ARS Pharmaceuticals, Inc.

SPRY: Is ARS Pharmaceuticals, Inc. Halal?

ARS Pharmaceuticals, Inc.

NASDAQHealthcareUS

$8.90

-5.62%

Market Cap: 883.8M

Compliance Status

Not Halal

Screened on Jul 17, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is ARS Pharmaceuticals, Inc. (SPRY) halal? Not Halal. Based on AAOIFI screening, ARS Pharmaceuticals, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

12.5% of 30.0% limit

What this means for you

Most scholars advise not holding SPRY

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 17, 2026

Compliance History

  1. Not Halalnow

    since Jun 2026

  2. Doubtful

    until the change above

  3. Not Halal

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR
Free · No credit card required

Track SPRY and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. (SPRY) halal to invest in?
ARS Pharmaceuticals, Inc. (SPRY) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did ARS Pharmaceuticals, Inc. get a F compliance rating?
ARS Pharmaceuticals, Inc. (SPRY) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 12.5% (limit 30%); interest-bearing deposits of 31.7% (limit 30%); prohibited income of 33.45% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change ARS Pharmaceuticals, Inc.'s Shariah verdict?
ARS Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is ARS Pharmaceuticals, Inc. re-screened for Shariah compliance?
ARS Pharmaceuticals, Inc. (SPRY) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 17, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.